{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:25:03Z","timestamp":1792013103154,"version":"4.4.0"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,6,14]]},"DOI":"10.18632\/oncotarget.7099","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:45:20Z","timestamp":1454287520000},"page":"35753-35767","source":"Crossref","is-referenced-by-count":54,"title":["Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Jennifer","family":"Varin","sequence":"first","affiliation":[{"name":"EA7331, Facult\u00e9 de Pharmacie de Paris, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laury","family":"Poulain","sequence":"additional","affiliation":[{"name":"Institut Cochin, D\u00e9partement d'Immuno-H\u00e9matologie, CNRS UMR8104, INSERM U1016, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Hivelin","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Plastique et Reconstructrice, H\u00f4pital Europ\u00e9en Georges Pompidou- AP-HP, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Nusbaum","sequence":"additional","affiliation":[{"name":"Service de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, H\u00f4pital Cochin, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Hubas","sequence":"additional","affiliation":[{"name":"Service de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, H\u00f4pital Cochin, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Laurendeau","sequence":"additional","affiliation":[{"name":"EA7331, Facult\u00e9 de Pharmacie de Paris, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Lantieri","sequence":"additional","affiliation":[{"name":"Service de Chirurgie Plastique et Reconstructrice, H\u00f4pital Europ\u00e9en Georges Pompidou- AP-HP, Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Dermatologie, Centre de R\u00e9f\u00e9rence des Neurofibromatoses, H\u00f4pital Henri-Mondor, AP-HP, Cr\u00e9teil, France"},{"name":"EA 4393 LIC, Universit\u00e9 Paris Est Cr\u00e9teil (UPEC), Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Vidaud","sequence":"additional","affiliation":[{"name":"EA7331, Facult\u00e9 de Pharmacie de Paris, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"Service de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, H\u00f4pital Cochin, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Pasmant","sequence":"additional","affiliation":[{"name":"EA7331, Facult\u00e9 de Pharmacie de Paris, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"Service de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, H\u00f4pital Cochin, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chapuis","sequence":"additional","affiliation":[{"name":"Institut Cochin, D\u00e9partement d'Immuno-H\u00e9matologie, CNRS UMR8104, INSERM U1016, Paris, France"},{"name":"Service d'H\u00e9matologie Biologique, H\u00f4pital Cochin, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Parfait","sequence":"additional","affiliation":[{"name":"EA7331, Facult\u00e9 de Pharmacie de Paris, Universit\u00e9 Paris Descartes, Sorbonne Paris Cit\u00e9, Paris, France"},{"name":"Service de Biochimie et de G\u00e9n\u00e9tique Mol\u00e9culaire, H\u00f4pital Cochin, AP-HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,1,31]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.7326\/0003-4819-144-11-200606060-00010","article-title":"American College of Physicians; American Physiological Society. Pathophysiology of neurofibromatosis type 1","volume":"144","author":"Korf","year":"2006","journal-title":"Ann Intern Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(09)70033-6","article-title":"Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1","volume":"10","author":"Legius","year":"2009","journal-title":"Lancet Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","article-title":"Plexiform neurofibromas","volume":"89","author":"Korf","year":"1999","journal-title":"Am J Med Genet"},{"key":"4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0140-6736(08)61277-5","article-title":"Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study","volume":"372","author":"Wolkenstein","year":"2008","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1212\/01.wnl.0000168830.79997.13","article-title":"Association between benign and malignant peripheral nerve sheath tumors in NF1","volume":"65","author":"Friedman","year":"2005","journal-title":"Neurology"},{"key":"6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","article-title":"Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis","volume":"69","author":"Lowy","year":"1992","journal-title":"Cell"},{"key":"7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/ng0296-144","article-title":"Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells","volume":"12","author":"Shannon","year":"1996","journal-title":"Nat Genet"},{"key":"8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Ratner","year":"2013","journal-title":"J Clin Invest"},{"key":"9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cub.2007.11.066","article-title":"TORC1 is essential for NF1-associated malignancies","volume":"18","author":"Cichowski","year":"2008","journal-title":"Curr Biol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S1470-2045(12)70435-7","article-title":"Treatment for plexiform neurofibromas in patients with NF1","volume":"13","author":"North","year":"2012","journal-title":"Lancet Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial","volume":"13","author":"Yu","year":"2012","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"Vidaud","year":"2014","journal-title":"Nature"},{"key":"13","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/ng.3124","article-title":"PRC2 loss amplifies Ras signaling in cancer","volume":"46","author":"Plass","year":"2014","journal-title":"Nat Genet"},{"key":"14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: epigenetic readers of lysine acetylation","volume":"13","author":"Knapp","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/0008-5472.CAN-13-1934","article-title":"Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors","volume":"74","author":"Le","year":"2014","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-06-0792","article-title":"The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1","volume":"12","author":"Kloog","year":"2006","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-013-1185-4","article-title":"Relevance of MPNST cell lines as models for NF1 associated-tumors","volume":"114","author":"Vidaud","year":"2013","journal-title":"J Neurooncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/0008-5472.CAN-05-3330","article-title":"Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues","volume":"66","author":"Muir","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"19","first-page":"713","article-title":"Role of noncoding RNA ANRIL in genesis of plexiform neurofibromas in neurofibromatosis type 1","volume":"103","author":"Vidaud","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/gcc.20921","article-title":"Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors","volume":"50","author":"Legius","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"21","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1535-7163.MCT-08-1008","article-title":"Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor","volume":"8","author":"Lev","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"22","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Khuri","year":"2005","journal-title":"Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1101\/gad.912401","article-title":"Hierarchical phosphorylation of the translation inhibitor 4E-BP1","volume":"15","author":"Sonenberg","year":"2001","journal-title":"Genes Dev"},{"key":"24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Sawyers","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nature Rev Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/1535-7163.MCT-07-2335","article-title":"Effectivetargeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors","volume":"7","author":"Ratner","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","article-title":"Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors","volume":"19","author":"Oda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"28","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation througha PI3K-dependent feedback loop in human cancer","volume":"118","author":"Pandolfi","year":"2008","journal-title":"J Clin Invest"},{"key":"29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor withandantitumor activity","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"30","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/bjc.2012.368","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma","volume":"107","author":"Banerji","year":"2012","journal-title":"Br J Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/jnen\/59.9.759","article-title":"Loss of neurofibromin is associated with activation of RAS\/MAPK and PI3-K\/AKT signaling in a neurofibromatosis 1 astrocytoma","volume":"59","author":"Guha","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"key":"32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","article-title":"The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation","volume":"36","author":"Blenis","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"33","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.18632\/oncotarget.1609","article-title":"Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of Schwann cell tumors reduces tumor grade and multiplicity","volume":"5","author":"Largaespada","year":"2014","journal-title":"Oncotarget"},{"key":"34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Chi","year":"2014","journal-title":"Nat Genet"},{"key":"35","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2174\/138161213804581918","article-title":"Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives","volume":"19","author":"Del Rio","year":"2013","journal-title":"Curr Pharm Des"},{"key":"36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1128\/MCB.01020-07","article-title":"Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression","volume":"28","author":"Zhou","year":"2008","journal-title":"Mol Cell Biol"},{"key":"37","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1074\/jbc.M707603200","article-title":"The bromodomain protein Brd4 stimulates G1 gene transcription and promotes progression to S phase","volume":"283","author":"Ozato","year":"2008","journal-title":"J Biol Chem"},{"key":"38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.celrep.2013.12.001","article-title":"BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction","volume":"6","author":"Le","year":"2014","journal-title":"Cell Rep"},{"key":"39","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Fedorov","year":"2010","journal-title":"Nature"},{"key":"40","doi-asserted-by":"publisher","first-page":"17698","DOI":"10.18632\/oncotarget.4131","article-title":"BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells","volume":"6","author":"Gardin","year":"2015","journal-title":"Oncotarget"},{"key":"41","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs","volume":"21","author":"Stussi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"42","doi-asserted-by":"crossref","first-page":"7501","DOI":"10.1021\/jm401088k","article-title":"Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains","volume":"56","author":"Jeffrey","year":"2013","journal-title":"J Med Chem"},{"key":"43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.15252\/emmm.201404430","article-title":"Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine","volume":"7","author":"L\u00e1zaro","year":"2015","journal-title":"EMBO Mol Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09553009314550251","article-title":"Radiosensitivityof human soft tissue sarcoma cell lines and skin fibroblasts derived from the same patients","volume":"63","author":"Okunieff","year":"1993","journal-title":"Int J Radiat Biol"},{"key":"45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/gcc.2870030111","article-title":"Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis","volume":"3","author":"Johnson","year":"1991","journal-title":"Genes Chromosomes Cancer"},{"key":"46","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/sj.onc.1207068","article-title":"Notch and Schwann cell transformation","volume":"23","author":"Kadesch","year":"2004","journal-title":"Oncogene"},{"key":"47","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1093\/hmg\/9.20.3055","article-title":"Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations","volume":"9","author":"L\u00e1zaro","year":"2000","journal-title":"Hum Mol Genet"},{"key":"48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/ejhg.2014.145","article-title":"Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?","volume":"23","author":"Vidaud","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"49","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood-2008-10-184515","article-title":"Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia","volume":"114","author":"Bouscary","year":"2009","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T21:22:58Z","timestamp":1654204978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,31]]},"references-count":49,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,6,14]]}},"alternative-id":["7099","26840085"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7099","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,31]]}}}